_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Ind-Ra expects revenue growth of over 12% in 2022.
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The hospital has recently launched Radionuclide therapy
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
Subscribe To Our Newsletter & Stay Updated
